GSK 649868

Drug Profile

GSK 649868

Alternative Names: GSK649868; GW649868; orexin-antagonist; SB-649868

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Amides; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sleep disorders

Most Recent Events

  • 03 Aug 2012 GlaxoSmithKline acquires Human Genome Sciences
  • 20 Aug 2009 Pharmacokinetics and pharmacodynamics data from animal studies in sleep disorders presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
  • 31 Jan 2007 Phase-I clinical trials in Sleep disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top